Tirzepatide is a synthetic polypeptide developed to replicate dual incretin activity under controlled laboratory conditions. As a GLP-1/GIP peptide, it contains a modified amino acid structure designed for stability and consistent handling in research workflows. With a molecular weight of approximately 4813.48 g/mol, it is commonly supplied as a purified lyophilized powder in a 15mg vial.
Tirzepatide research focuses on its involvement in coordinated metabolic signaling. It enables the study of how dual-acting peptide systems influence the interaction between endocrine responses and cellular activity in experimental models.
Tirzepatide (15mg) Key Features & Specs
- Subcategory: Weight Loss & Metabolic Peptides
- Strength: 15mg
- CAS: 2023788-19-2
- Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight: 4813.48 g/mol
- Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
- Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE
For laboratory research use only.
Tirzepatide (15mg) Research Uses
Tirzepatide is being explored in studies focused on metabolic coordination and endocrine signaling. It has been studied under controlled conditions for its effects on glucose-related processes, insulin-associated responses, and energy balance.
Ongoing research also evaluates its role in appetite-related signaling and how dual-acting peptides may influence system-wide metabolic regulation. These studies aim to better understand how multiple signaling pathways respond to a single compound.
Tirzepatide (15mg) Insights & Observed Findings
Data from research include findings from in vitro and preclinical models, where concentrations vary by study design and biological targets. These studies observe how the peptide behaves under different experimental conditions.
Research on Tirzepatide has documented patterns in metabolic signaling and cellular responses. These observations are limited to controlled environments and guide further experimental exploration rather than indicating clinical use.
Tirzepatide (15mg) Handling & Storage
- Store Tirzepatide (15 mg) at –20°C in a controlled laboratory setting, protected from light and moisture.
- After reconstitution, store the solution refrigerated.
- Handle the reconstituted solution carefully to maintain consistency in experimental conditions.
- Avoid repeated freeze-thaw cycles.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- National Center for Biotechnology Information. PubChem Compound Summary for CID 156588324, Tirzepatide. https://pubchem.ncbi.nlm.nih.gov/compound/156588324
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
- Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. doi:10.1073/pnas.2116506119
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
- Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315